Four Corners Property Trust (FCPT) Q2 2026 earnings review
Transformational Scale, But Per-Share Growth Stalls
FCPT delivered a stable Q2, but the real story is the post-quarter $268M acquisition of the Mission Pet Health (MPH) portfolio. This blockbuster transaction accelerates FCPT's diversification, permanently altering the portfolio by diluting Darden exposure to a record-low 41%. However, aggressive top-line expansion is not flowing down to shareholders: while rental revenue grew 8% YoY, Adjusted Funds From Operations (AFFO) per share has stagnated at $0.45 for four consecutive quarters. With leverage steadily climbing to 5.2x, management is executing flawlessly on portfolio construction, but must now prove these investments can generate meaningful per-share accretion.
🐂 Bull Case
The 102-property Mission Pet Health acquisition completely de-risks the legacy Darden concentration. Expanding Medical Retail to 16% of pro forma ABR provides a massive, recession-resistant growth runway.
FCPT successfully recast its credit facility, upsizing with a $400M term loan at a highly attractive SOFR + 0.90% margin. Locking in cheaper debt secures healthy spreads against ~6.8% acquisition yields.
🐻 Bear Case
Despite deploying hundreds of millions into 'accretive' acquisitions, AFFO per share growth has ground to a halt. Equity issuance and higher base interest rates are completely neutralizing top-line gains.
Net debt to Adjusted EBITDAre has increased sequentially for four quarters, rising from 4.5x a year ago to 5.2x today—and this is before fully absorbing the $268M MPH transaction.
⚖️ Verdict: ⚪
Neutral. FCPT's strategic pivot away from casual dining dependency is an undeniable success, and their balance sheet management is commendable. Yet, the lack of AFFO per share growth makes it difficult to justify a pure growth premium. Investors are essentially trading yield for safety.
Key Themes
Mission Pet Health: A Transformational Acquisition
Accelerating diversification. FCPT closed the largest deal in its history on July 16, acquiring 102 veterinary properties for $268M. This single transaction reduces Darden ABR from 100% at the 2015 spin-off to just 41% pro forma. The portfolio features strong 6.0x rent coverage, 10-year master leases, and >2% annual escalators, instantly making Medical Retail a core pillar of the company.
Debt Optimization Expands Investment Spreads
Stable funding costs. FCPT recast its credit facility, adding a new $400M 5-year term loan at SOFR + 0.90% (an all-in rate of ~4.5%). Lenders also agreed to lower the margins on $800M of existing term loans to the same rate, generating ~$450K in annual interest savings. With acquisition yields holding at ~6.8%, this secures a highly profitable >200bps investment spread.
Transition to Monthly Dividends
FCPT announced a shift from quarterly to monthly dividends ($0.1222 per share) starting in Q3 2026. While mechanically neutral to the bottom line, this is a highly shareholder-friendly move that aligns distributions with the monthly cadence of FCPT's rent collections.
Stagnant Per-Share Accretion Contradicts Growth Narrative
Reversing per-share momentum. Management repeatedly highlights highly accretive spreads, yet AFFO per share has remained completely flat at $0.45 since Q3 2025. While Q2's AFFO of $0.45 represents a 1.4% YoY increase (vs $0.44 in 25Q2), sequential growth has evaporated. FCPT is building a larger, safer company, but it is currently doing so without delivering meaningful bottom-line growth to existing shareholders.
Consistent Leverage Creep
Decelerating balance sheet flexibility. Management touted an 'over-equitized' balance sheet in late 2025 when leverage was 4.9x. By Q2 2026, Net Debt to Adjusted EBITDAre climbed to 5.2x. While still comfortably within the 5.0x-6.0x target, the trajectory indicates the buffer is shrinking, especially as the $268M MPH deal was largely debt-funded.
Macro Dependence on Sticky Cap Rates
Macro risk. The company relies entirely on the arbitrage between its ~4.5% debt cost and 6.8% acquisition cap rates. If elevated private credit competition compresses net lease cap rates, or if interest rates remain structurally higher, FCPT's ability to drive accretive volume will be severely curtailed.
Proprietary Sourcing Scorecard
FCPT continues to leverage its proprietary 'triple filter' scorecard to execute on 'onesies and twosies'—granular, sub-$3M properties. This unique sourcing tech and disciplined underwriting process insulates the company from the fierce private equity bidding wars typically seen in large-scale retail portfolios.
Other KPIs
Accelerating sequentially from $26.2M in Q1. The company acquired 23 properties at a 6.8% initial cash yield. 64% of the volume was directed toward Auto Service, demonstrating a continued focus on e-commerce-resistant essential services prior to the massive Medical Retail pivot in July.
Stable. Fundamentals remain best-in-class. Occupancy held steady at 99.5%, and rent collection for Q2 was 99.7%. Strong tenant EBITDAR coverage of 5.2x ensures highly secure cash flows across the portfolio.
Guidance
Stable. Management reaffirmed its long-term leverage target. However, moving to 5.2x at Q2-end signals they are actively utilizing the balance sheet capacity they preserved throughout 2025.
Stable. The declared monthly dividends for July, August, and September total $0.3666 per quarter, perfectly matching the prior quarterly rate. The implied annual yield remains robust and highly secure.
Key Questions
Path to Per-Share Growth
With AFFO per share flat sequentially for four quarters, at what point will the massive acquisition volume, particularly the $268M MPH deal, overcome financing dilution and drive actual bottom-line growth for shareholders?
Leverage Trajectory
Net debt to EBITDAre crept up to 5.2x prior to closing the MPH acquisition. Post-transaction, how close will FCPT get to its 6.0x ceiling before tapping the equity markets to rebalance?
Underwriting Private Equity Tenants
Mission Pet Health is operated by a private equity sponsor (Shore Capital) who also sold the real estate. How does FCPT's credit underwriting adapt when dealing with highly-leveraged, PE-backed rollup tenants versus traditional public companies like Darden?